Search

General Information

June 5, 2025
EHA2025 Congress platform opens

June 12-15, 2025
EHA2025 Milan, Italy - In-person and live stream

Location 
Allianz MiCo, Milano Convention Centre

August 15, 2025
EHA2025 Congress platform closes

 
 

Scientific Program Committee (SPC) Chair
Prof.

Read more

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…

Read more

EHA Education & Mentoring Award

“Educating and mentoring are a brain to pick, an ear to listen, and a push in the right direction. ”

Through this award, EHA recognized excellent teachers and mentors at any stage of their career.

Read more

Highlights of the SWG

SWG business meetingWe held a key strategic SWG business meeting on November 29, 2023, at the EHA offices in The Hague. During the meeting, we discussed the future plans and priorities of our SWG.

Read more

Report VIRTUAL EHA-SWG Scientific Meeting on Immunotherapy

This scientific meeting was organized together with the EHA Scientific Working Group on Immune Therapies for Hematological Disorders.

Read more

Meetings Sponsor Program

The European Hematology Association (EHA) is a membership organization serving clinicians and researchers with an active interest in hematology in Europe and beyond. We bring together relevant stakeholders to promote excellence in patient care through education, research, and advocacy.

Read more

Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests

In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more